Indeed, lack of favorable outcome for NOTCH1 mutation in T‐ALL has been reported, particularly in studies treated with regimens other than BFM‐ALL protocols.45, 46, 47, 48 Enrichment of ETP (33%) in our cohort could be attributable to the negative impact of NOTCH1 mutation since it is well‐known for worse clinical outcome.49, 50 However, to the best of our knowledge, it is unknown if N/F/R/P classifier retains prognostic power after stratified by immunophenotype. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.